An analysis of real-world dosing and effectiveness of pegfilgrastim biosimilars found the clinical benefits of preventing febrile neutropenia in patients with intermediate to high risk come at acceptable financial costs compared with filgrastim biosimilars.
Febrile neutropenia (FN) hospitalizes approximately 60,000 US patients every year and costs $28,000 per admission. A new study has shown that biosimilar pegfilgrastim (PEG) as primary prophylaxis in patients with cancer and an intermediate to high risk of chemotherapy-induced neutropenia can save on spending.
The findings were published in Future Oncology.
FN also causes delays, dose reductions, and discontinuation of chemotherapy schedules, all of which reduce survival rates for patients with cancer. The biologics filgrastim (FIL) and PEG reduce FN incidence and are recommended to prevent neutropenia. PEG is a long-acting formulation that has advanced management of neutropenia in patients with cancer, but has higher costs compared with FIL.
“The benefits of PEG biosimilars will be multiple,” the authors explained. “The first impact will be in welcome savings for hard-pressed hospital drug budgets. The second benefit will be in changing the balance of real-world value between the long-acting PEG and its short-acting alternative, FIL, which is one of the objectives of the present study.”
They used real-world data to assess the cost-effectiveness of PEG vs FIL in patients at high-risk of FN (> 20% risk) and at intermediate-risk of FN (10%-20% risk). They looked at PEG biosimilars, PEG reference in a prefilled syringe, PEG reference in an on-body injector, FIL biosimilars, and FIL reference; however, since the biosimilars always outperformed the reference products, the researchers focused their findings in the study on the biosimilars.
In the high-risk group:
In the intermediate-risk group:
Probabilistic sensitivity analyses determined the probability of PEG biosimilar being cost-effective compared with FIL biosimilar at a willingness-to-pay threshold of $100,000 per QALY gained, per LY gained, and per FN event avoided to be 100%, 100%, and 100%.
In addition to primary prophylactic use of biosimilar PEG being cost-saving in patients with a high-risk of FN, extending PEG prophylaxis in patients with intermediate-risk of FN is cost-effective, assuming a threshold for the WTP per QALY gained of $50,000 to $200,000, the authors determined.
“The introduction of PEG biosimilar urges a re-evaluation of current treatment guidelines for G-CSF [granulocyte colony-stimulating factors] use in neutropenia management,” the authors concluded. “A multidisciplinary effort that involves treating oncologists, nurses, pharmacists and patients is needed to fully release the value of G-CSF biosimilars.”
Reference
Cornes P, Kelton J, Liu R, Zaidi O, Stephens J, Yang J. Real-world cost-effectiveness of primary prophylaxis with G-CSF biosimilars in patients at intermediate/high risk of febrile neutropenia. Future Oncol. Published online March 31, 2022. doi:10.2217/fon-2022-0095
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Similar Survival, Safety for Bevacizumab Biosimilar vs Originator in Colorectal Cancer
February 8th 2025A retrospective observational study found no significant differences in progression-free survival or safety in patients with colorectal cancers in Japan treated with ABP 215, Amgen’s bevacizumab biosimilar, or reference bevacizumab (Avastin), and estimated cost savings of 800,000 Japanese yen (approximately $5100) per patient with the biosimilar.